Literature DB >> 7564352

Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients.

L Vaur1, C Dutrey-Dupagne, J Boussac, N Genes, M Bouvier d'Yvoire, F Elkik, P A Meredith.   

Abstract

A double blind randomised comparison of two angiotensin-converting enzyme (ACE) inhibitors was made in a study in which ambulatory blood pressure was monitored over a steady-state dosage interval and the subsequent 24-h period, the latter being designed to mimic a missed dose of drug. The blood pressure responses on active therapy were compared to an identical recording made at the end of a 3-week placebo run in period. Eighty-eight essential hypertensives were treated with a morning dose of either trandolapril 2 mg or enalapril 20 mg. Mean systolic (SBP) and diastolic blood pressure (DBP) were calculated on each of the following periods: daytime (8:31 a.m.-10:30 p.m.), nighttime (10:31 p.m.-6:30 a.m.), and early morning (6:31 a.m.-8:30 a.m.). Trough/peak was calculated for each group both on active treatment and after a missed dose. Twelve patients were excluded from analysis before opening the randomisation code because of inadequate ambulatory blood pressure monitoring (ABPM) recordings. Demographic data, placebo-period office blood pressure, and ABPM recordings were not significantly different between the two groups. Both trandolapril and enalapril effectively reduced blood pressure over the 24-h period. Twenty four-hour ambulatory SBP and DBP decreased from 148 +/- 14/92 +/- 10 mm Hg to 135 +/- 14/83 +/- 10 mm Hg in the trandolapril group (p < 0.001). The same parameters decreased to a quite similar extent after enalapril, from 143 +/- 13/91 +/- 5 mm Hg to 133 +/- 15/83 +/- 8 mm Hg (p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564352     DOI: 10.1097/00005344-199507000-00020

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

Review 1.  Modeling and simulation of adherence: approaches and applications in therapeutics.

Authors:  Leslie A Kenna; Line Labbé; Jeffrey S Barrett; Marc Pfister
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 2.  The implications of noncompliance with antihypertensive medication.

Authors:  B Girvin; G D Johnston
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 3.  Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  D C Peters; S Noble; G L Plosker
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

4.  Sustained blood pressure-lowering effect of aliskiren compared with telmisartan after a single missed dose.

Authors:  Rainer Düsing; Patrick Brunel; InYoung Baek; Fabio Baschiera
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-09       Impact factor: 3.738

5.  Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ.

Authors:  Thomas Mengden; Hans Vetter; Eric Tousset; Sakir Uen
Journal:  BMC Cardiovasc Disord       Date:  2006-08-30       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.